Introduction
Prevention of end-stage renal disease (ESRD) by early detection and treatment is an important tool to stop the growing need for renal replacement therapy. The last decade has brought forward strong reasons for such an approach. The incidence of ESRD has increased dramatically, which is mostly attributed to type 2 diabetes 1 and improved survival from atherosclerotic vascular disease. 2 This increased rate of ESRD further augments the already high burden on the patient and doctor, as well as on health care economics. Indeed, patients entering renal replacements program are fifteen times more likely to die relative to subjects in the general population.
The target population for prevention still needs to be defined. There is no doubt that prevention in patients with glomerulonephritis, pyelo-and interstitial nephritis and diabetic renal disease is feasible. For non-diabetic subjects, logical steps are to identify those who are also at risk for the consequences of progressive renal disease, such as subjects with (undiagnosed) slight renal dysfunction. Only recently, the high prevalence (~10%) of mild to moderate renal insufficiency (glomerular filtration rate, GFR <60 ml/min/1.73 m 2 ) in the population has been recognized. 3, 4 In mild renal insufficiency, (pre)diabetes, hypertension and other risk factors are already highly prevalent. 5, 6 Moreover, renal insufficiency itself appears to be a major predictor of cardiovascular mortality, in the general population as well as in subjects with cardiovascular disease. 7, 8 Considering the high burden of mild renal impairment, this group of patients may be an eligible one in the primary prevention of disease and mortality. To identify those individuals at high risk we need a minimal set of essential risk factors.
The progression of renal function loss is dictated by several classical risk factors such as hypertension, proteinuria, obesity, smoking, and hyper-or dyslipidemia, all of which are potentially modifiable. Elevations in blood pressure are a strong independent risk factor for ESRD. 9 Proteinuria has been more recently established as a key risk marker (and likely a factor) 10 of renal function decline in subjects with primary renal disease and nephropathy from type 1 or 2 diabetes. A proportion of diabetic and hypertensive subjects with even lower amounts of urinary protein or albumin excretion (microalbuminuria) will eventually progress to proteinuria and subsequent renal function decline. 11, 12 Obesity is a risk factor for the development of ESRD in the population. 13 Recent evidence suggests that obesity-related glomerulosclerosis is a serious clinical condition with an adverse long-term renal outcome. 14 The incidence of this obesity-related glomerulopathy has increased tenfold over the last fifteen years in the population. Furthermore, Praga et al underlined the impact of obesity by showing that initially healthy obese subjects (BMI >30 kg/m 2 ) were at high risk for developing proteinuria and loss of renal function after unilateral nephrectomy as compared to lean subjects. 15 Smoking has also been demonstrated to be a risk factor for progressive renal 109 109 function loss. Epidemiological data reveal that smoking has deleterious effects on the kidney in populations with as well as without primary renal disease. In the general population and in subjects with essential hypertension, smoking is dose-dependently related to albuminuria and decreased glomerular filtration rate. 16 Smoking also increases the risk of renal failure in the general (male) population. 9 Hyperlipidemia has been shown to determine decline of renal function and to predict the onset of microalbuminuria. 17 A dyslipidemic lipid profile, namely low high-density lipoprotein and elevated low-density lipoprotein / triglyceride levels, has also been shown to be related to microalbuminuria 17, 18 and renal function decline. 19 Intervention studies for all (or most) of the above risk markers/factors, including proteinuria, 20, 21 hypertension, 20,21 obesity 22 and hyperlipidemia, 17 show indirect or direct evidence for renal protection through a change in intermediate and hard renal endpoints.
Interestingly, global cardiovascular (CV) risk assessment involves the same classical risk markers and risk factors as for renal risk assessment. There is a host of evidence for blood pressure, 23 obesity, 24 smoking, 25 and hyperlipidemia 26 as predictors of CV outcome. For CV outcome, intervention in each of these factors has proven clear benefit. [27] [28] [29] In addition, there is increasing evidence that (micro)albuminuria is also a risk marker for CV disease and mortality in the population. [30] [31] [32] [33] Nevertheless, much of the total risk still remains to be explained and optimal intervention still leaves a substantial amount of risk. This has stimulated the search for novel, easy to obtain CV risk markers or factors, recently resulting in a host of biochemical markers indicative of putative pathophysiological mechanisms for CV disease such as inflammation, vascular dysfunction, dysregulation of the coagulation and fibrinolysis system, and others. As will be discussed, these markers add independent prognostic information about risk in various patient groups. 34 These novel markers often show high risk estimates, 34 often higher than classical risk factors. Table 1 shows these risk markers and the relative evidence for their role in predicting CV and renal disease risk.
For example, high-sensitive C-reactive protein (CRP), a sensitive marker of inflammation, has been proposed as a novel predictor of CV outcome: it has been proposed a stronger CV risk predictor than low-density lipoprotein cholesterol in many studies. It predicts risk in absence of hyperlipidemia or elevated blood pressure, and CRP adds prognostic information in risk scoring systems. This has had already such a strong impact that a large intervention trial was undertaken to alter the natural course of CV disease by lowering of a biochemical parameter like CRP by a cholesterol-lowering drug (JUPITER). 35 This would be by analogy with the observation that some antihypertensive drugs such as those intervening in the renin-angiotensin-aldosterone system, reduce CV risk beyond their effect on blood pressure lowering (e.g. LIFE trial). 36 Novel risk markers are expected to add to the existing classical repertoire as a possible target for treatment. 
Lipid-associated factors c)
Small dense LDL ++ + [215] [216] [217] [218] [219] [220] [221] [222] ? ?
Lipoprotein(a) ++ ++ 223, 224 = + 214, 225 Apolipoproteins A1, A2 ++ + [226] [227] [228] [229] = = 225, 230 Apolipoprotein B ++ ++ [226] [227] [228] [229] ++ ++ 160, 225, 230, 231 Oxidised LDL + + [232] [233] [234] [235] [236] [237] ? ?
Others Fasting (pro)-insulin) ++ + [238] [239] [240] [241] [242] [243] [244] [245] [246] prospective studies (at least 2) show a statistically significant association between the parameter and outcome. +:
at least 25% of all prospective and/or cross-sectional studies show a statistically significant association between the parameter. =: less than 25% of all prospective and/or cross-sectional studies show a statistically significant association between the parameter. ?: association between the parameter and outcome is unknown. The criterion for a significant association is met if the parameter is suggested to add prognostic information beyond the classical risk factors. b) Thrombomodulin is usually inversely associated with CV outcome. The study by Wu et al showed an interaction between thrombomodulin and sICAM on the risk of mortality. c) Apart from classical risk factors, the independent contribution of lipid abnormalities to outcome is almost always investigated in the context of other lipids. With respect to lipid abnormalities, the criterion for a significant association is met if the association between the lipid parameter and outcome is suggested to be independent.
d) The correlation between plasma homocysteine levels and GFR (or serum creatinine) in cross-sectional studies is very high. With respect to renal function, elevations of homocysteine levels are yet considered to be an epiphenomenon, and therefore not causally involved in GFR deterioration. In this review, we will describe what the pathophysiological role of these pathways could be, which markers are available and how they are related to the different intermediate and hard endpoints.
We will do this both for CV outcome and for renal outcome.
Chapters

Markers of inflammation
C-reactive protein and CV outcome
Undoubtedly, most data on novel risk markers and CV outcome in the population are available for CRP. How good is the evidence of the role of CRP in CV risk prediction? After earlier studies had shown that CRP was able to predict future coronary events in patients with both stable and unstable angina, 37 large epidemiological studies showed similar results in subjects at a relatively low absolute risk of mortality. Elevated levels of CRP were associated with CV endpoints including (non)fatal myocardial infarction, stroke and peripheral artery disease. Most studies show significant associations between elevated CRP levels and these endpoint parameters in the population (Table   1 ), 38-64 except for some studies. [65] [66] [67] [68] [69] [70] [71] [72] Most authors therefore suggest that CRP has an added value in global CV risk assessment, 73 while others state that CRP does not add to absolute risk assessment according to the Framingham risk score. 71 The added value of CRP usually persists after adjustment for conventional risk factors, and its 'independent' value in comparison with other novel risk markers (e.g. interleukin-6, fibrinogen, microalbuminuria, leptin et cetera) warrants further research. A recent meta-analysis showed that the increased risk conveyed by high serum CRP levels is about 1.5-fold when comparing the lowest tertile with the upper tertile of the CRP distribution. 74 Interstingly, an earlier meta-analysis showed a risk estimate of 2-fold. 50 In the former meta-analysis, CRP showed a risk estimate which was much lower than those risk estimates based on blood pressure and total cholesterol. 74 This is in sharp contrast with reports mentioned before, which showed superiority of CRP relative to other risk factors. Possibly, some publication bias is present in earler studies.
CRP: meachnisms of CV outcome
Before implementing a risk factor (or marker) into clinical practice, concepts concerning its role 113 113 in biology and vascular pathophysiology are suggested, this happening to cholesterol decades ago. What are the current concepts relating CRP to CV outcome? CRP, the prototypic acute-phase protein, is a sensitive but non-specific marker of inflammation. In case of infection or tissue injury, it is quickly upregulated and produced by the liver mainly through stimulation of its synthesis by interleukin-6 and other cytokines.
What can be the mechanisms behind the relation between inflammation and CV events?
Inflammation may be related to CV outcome in various ways. First, atherosclerosis is a low-grade inflammatory disease, this inflammation evolving at young age culminating in the disruption of an unstable plaque. 75 The generally held assumption is that CRP reflects the inflammatory status or activity at atherosclerotic sites. This is certainly possible, though data are currently conflicting.
Studies in favour of such a role show that CRP is associated with the extent of atherosclerosis measured at various sites of the vascular tree. 76 CRP levels are generally higher in subjects with more severe atherosclerosis, e.g. unstable angina. However, other studies suggest that the risk held by CRP is independent of atherosclerosis. For instance, it has been shown that CRP adds to risk of Table 2 . Direct role of C-reactive protein in atherogenesis.
Localisation
Localises in shoulder regions of (vulnerable) plaques
Depositions with inflammatory cells and lipid-rich areas
Co-localisation with complement in infarcted tissue
CRP ligand binding
Binds selectively to LDL, especially oxLDL Aggregated and/or ligand-complexed CRP activates complement
Phagocytic function
Enhances LDL uptake by macrophages
Vascular function
Decreases NO synthase expression in endothelial cells
Decreases prostacyclin release from human aortic cells
Relaxes human vessels
Leukocyte adhesion
Induces expression of leukocyte adhesion molecules
Induces secretion of MCP-1
Thrombosis
Increased rate of thrombosis in CRP-transgenic mice Tissue factor production by macrophages stroke and myocardial infarction beyond the risk held by atherosclerosis (intima-media thickness) measured at level of the carotid artery. 59, 63 Second, since a causal role of CRP is suggested in epidemiological research, it may be that CRP itself is involved in vascular injury. In this case, CRP may be viewed as a risk factor rather than a risk marker. Table 2 lists the proposed biological and pathophysiological properties of the CRP molecule.
Considering these properties, a causal role of the molecule may be more apparent in acute situations (myocardial necrosis, plaque instability et cetera), 77, 78 rather than at the population level. At the population level, CRP predicts mortality over an extended period up to 20 years with a constant hazard. 39 Therefore, this makes a direct role of CRP less unlikely in the population setting.
A third possibility by which CRP may be related to an increased risk of CV events is CRP as an epiphenomenon. Elevated CRP levels may either reflect inflammation elsewhere in the body or inflammation in association with other putative CV risk factors. Notably, the positive association of CRP with body mass index (BMI) is very strong, and may even be stronger in abdominal obesity. 79 In children, in whom atherosclerosis is absent, BMI is by far the strongest correlate of CRP. 80 These associations may in part be due to the fact that adipocytes secrete interleukin-6 and tumor necrosis factor-α in high quantities, the former being the main stimulator of hepatic CRP production. In conjunction to the association with abdominal obesity, CRP levels strongly correlate with features of the metabolic syndrome and insulin sensitivity. 81 Weight loss and concomitant improvent of insulin resistance clearly lowers CRP. 82,83 Thus, CRP may reflect an abnormal metabolic profile, which leads to an increased risk of atherothrombotic events. This is further strengthened by the fact that CRP predicts the incidence of type 2 diabetes. 84
CRP: mechanisms in renal outcome
What can be the mechanisms behind the association between low-grade inflammation and renal disease? Again, atherosclerosis may be a key element. Interestingly, it has been postulated that the renal analogue of the inflammatory process observed in atherosclerosis is glomerulosclerosis, 75 the final common pathway of kidney damage as found in proteinuria, hypertension, obesity and the age-related decline of renal function. Glomerulosclerotic lesions disclose epithelial-and endothelialcell injury and dysfunction with glomerular influx of inflammatory cells like monocytes (foam cells) and lymphocytes, and mesangial expansion as paralleled by smooth muscle cell proliferation in atherosclerosis. 75, 85 Second, risk factors like obesity, hypertension and smoking may enhance a decline in kidney function through inflammation. Stengel et al showed independent effects of physical inactivity, obesity and smoking as risk factors for the incidence of ESRD. 13 Unfortunately, these studies relating risk factors to the incidence of ESRD did not include measurements of inflammatory markers.
Finally, tubulointerstitial inflammation and fibrosis are the most constant features of renal function decline in various animal models (diabetes, hypertension, ischemia, renal ablation and proteinuria). This inflammation is accompanied by influx of immune cells like macrophages and monocytes. 86 The cell influx enhances proinflammatory cascades in the diseased kidney like superoxide formation, activation of the angiotensin system and others. Interestingly, the concept of renal inflammation in progressive kidney disease intertwines with the concept of hemodynamically induced renal injury. Only recently, it has been shown that dual intervention on renal hemodynamics (angiotensin-converting enzyme inhibitor) and inflammation (mycophenolate mofetil) maximised renoprotection in animals. 87 Whether renal (tubulointerstitial) inflammation induces CRP production by the liver is not known.
CRP as a predictor of renal outcome -GFR
Some epidemiological studies have focussed on the relation between inflammatory markers and renal disease outcome.
General population
Regarding the similarities between atherosclerosis and glomerulosclerosis on the one hand and inflammation and CV events on the other hand, we and others recently found evidence of a link between CRP and a decreased glomerular filtration rate (GFR) in the general population. 88, 89 We found that CRP was related to a diminished GFR, but also with renal hyperfiltration, the latter being explained by increased body fat. 88,89 Possibly, early inflammatory processes related to high body fat may predispose the kidney to hyperfiltration-related renal function decline. Shlipak et al similarly showed that CRP, interleukin-6 and fibrinogen were elevated in a dose-dependent fashion across levels of decreased kidney function in the population either in the presence or absence of manifest atherosclerosis. 88,89 These associations were found independent of conventional renal risk factors. Thus, inflammation seems to be present in early renal disease in the general population. From these cross-sectional data however, no conclusions can be drawn whether inflammation was cause or consequence of the decreased renal function.
Chronic kidney disease
In predialytic patients with kidney disease comprising of a variety of aetiologies, CRP and interleukin-6 levels were inversely correlated with creatinine clearance as shown in two crosssectional studies. 90, 91 In another heterogeneous patient group with chronic kidney diseases (diabetic and non-diabetic), the investigators of the Modification of Diet in Renal Disease Study prospectively found a relation between transferrin, a negative acute-phase protein, and the decline of renal function. 92 In a later report however, they did not prospectively find a relationship between CRP and progression of kidney disease. 93 
Diabetes
Whether inflammatory parameters are associated with levels of GFR or deterioration of GFR over time in patients with type 1 or 2 diabetes is as yet unknown.
CRP as a predictor of renal outcome -Albuminuria
The general population
Other data supportive of a role of inflammation in renal disease come from studies regarding another marker of (incipient) renal disease, namely microalbuminuria. 94 Festa et al showed a link between inflammatory markers and microalbuminuria in non-diabetic subjects from the general population. 94 In non-diabetic subjects from a Dutch population, Jager et al prospectively showed that CRP was related to the incidence of microalbuminuria. 95 Such a link was also provided in premenopausal obese women. 96 Recently, we showed that CRP modified the relation between blood pressure and microalbuminuria. 97 We hypothesised that inflammation increases the likelihood of increased glomerular leakage of albumin in response to blood pressure. This glomerular leakage may either involve increased transmission of systemic blood pressure or a decreased barrier function of the glomerulus.
Chronic kidney diseaese
Whether albuminuria in chronic kidney disease is related to CRP or other inflammatory markers is unknown. However, asymptomatic proteinuric patients have higher CRP levels as compared to healthy subjects. 98 
Diabetes
The participation of inflammation in the pathogenesis of early nephropathy was also hypothesised by Navarro et al, 99 who showed a dose-dependent rise in micro-and macroalbuminuria in type 2 diabetic patients with increasing serum CRP and tumour necrosis factor-α levels. These correlations were remarkably high (r=0.68). Urinary TNF-α was correlated with albuminuria to the same extent, however, urinary TNF-α was unrelated to serum TNF levels. This observation suggests that local inflammatory activity in the kidney results in albuminuria, which is independent of systemic inflammation. 99 Further, the incidence of microalbuminuria is increased in type 2 diabetic subjects with elevated levels of CRP. 100 The development of albuminuria in the latter patient group was determined by the gradual and concomitant rise with CRP over time.
Altogether, these data provide evidence of involvement of inflammation in the pathogenesis of early nephropathy in type 2 diabetes.
Elevated levels of inflammatory markers in type 1 diabetes yield an increased risk for urinary albumin losses in the range of micro-to macroalbuminuria in cross-sectional studies, 101,102 but this has not yet been studied in prospective studies.
Conclusion. In line with the abundant evidence of CRP as a marker of CV outcome, recent evidence suggests that this molecule may also serve as an early predictor of renal function decline and early nephropathy.
Markers of endothelial function
2.1 Microalbuminuria
Albuminuria and CV outcome
Aside from the fact that albuminuria is a renal outcome parameter as described in previous paragraphs, microalbuminuria itself is also regarded as a marker of CV risk. An important concept is that generalised endothelial damage along the vascular tree is being disclosed by traces of urinary albumin loss. In line with the homogeneity between renal and CV risk factors, we have recently shown that elevated levels of urinary albumin excretion independently predicted all-cause and CV mortality in the general population. 31 This was confirmed in a Norwegian population based study. 32 For each doubling of albuminuria, subjects faced a 29% increased relative risk of CV death. Interestingly, the risk held by albuminuria was independent of conventional risk factors and comparable across strata of well-known risk factors. Romundstad et al found that the relationship between albuminuria and the risk of all-cause mortality was generally stronger in men than in women, especially in hypertensive subjects. 32 These results extended earlier results found in elderly and hypertensive populations 33,103 as well as in diabetes. 104 Thus, it may well be that albuminuria can be used as an additive tool in absolute CV risk assessment in the general population, like CRP.
Albuminuria: meachnisms of CV outcome
The pathophysiological role and mechanisms of albuminuria in diabetic and hypertensive renal disease, 105, 106 but also in the general population 107 have been reviewed elsewhere. Thus, here we only discuss the role of albuminuria as a parameter in CV outcome. The relation between albuminuria and CV outcome could be explained by systemic effects of a mildly injured kidney in blood pressure and salt regulation, in which glomerular autoregulation is impaired. Alternatively, albuminuria could represent a more generalised endothelial dysfunction, thus allowing a vascular origin for CV risk. Finally, albuminuria could be a sign of the metabolic syndrome, this by itself causing increased CV risk.
Microalbuminuria may be viewed as a pressure-related phenomenon. It could appear when glomerular autoregulation is impaired. This may be the reason why systemic blood pressure is most strongly associated with albuminuria in the population and in diabetes. 97, 106 Both increased and decreased effective circulating volume, the latter due to efferent vasoconstriction resulting in an elevated filtration fraction, are associated with albuminuria. 108 Increased salt intake is also a wellknown determinant of an increase in urinary albumin. Conceptually, every (risk) factor that alters glomerular autoregulation may enhance the development of albuminuria. It is however unknown whether proxy markers of volume/salt status can explain the risk of death which is attributed to (micro)albuminuria.
Microalbuminuria can also be regarded as a marker of underlying generalised endothelial or vascular dysfunction. The fact that the risk of death held by albuminuria is more related to death from CV causes than from non-CV causes strengthens the concept of a generalised vascular involvement. 108 On the other hand, while some authors found an increased transcapillary escape rate of albumin in microalbuminuric subjects, 109 others failed to show such a relation. 110 Furthermore, the correlation of albuminuria with the extent of atherosclerosis seems limited at the population level. [111] [112] [113] Recent evidence also indicate that other markers of endothelial dysfunction, such as von Willebrand factor and leukocyte adhesion molecules cannot explain the risk of death held by albuminuria. 95 Lastly, albuminuria could also be a compound factor associated with the metabolic syndrome. This is certainly possible, since albuminuria is related to hyperinsulinemia and insulin resistance, 114 and it also predicts the onset of type 2 diabetes in the population. 115 Further, microalbuminuria is associated with almost all components of the metabolic syndrome, 116 especially blood pressure. 106 Kuusisto et al, for instance, showed that the simultaneous occurrence of hyperinsulinemia and albuminuria identified a patient group with an inexorably high risk of CV death. 18 On the other hand, parameters of the metabolic syndrome such as blood pressure, obesity and hyperlipidemia, usually cannot explain the excess CV risk held by albuminuria itself. Smoking, an other important risk factor for the development of albuminuria, 117 cannot explain the excess risk in albuminuric subjects either.
Albuminuria as a predictor of renal outcome -GFR The general population
Considering its widespread clinical use in diabetes care, microalbuminuria is undoubtedly one of the most promising parameters to be used in the general population to identify subjects at increased renal risk. 118 Whether the presence of albuminuria in the general population will lead to renal function 119 119 decline in time is being studied at present in a large cohort in the Netherlands. We have described the pattern of renal function abnormalities in non-diabetic subjects from the population in a crosssectional study. Low levels of albuminuria were associated with an elevated creatinine clearance, suggestive of renal hyperfiltration, whereas gross albuminuria was associated with a decreased creatinine clearance relative to subjects with normal albuminuria, 118 
Diabetes
There is no need to built a case for albuminuria as a predictor for renal risk in chronic kidney disease and type 1 and 2 diabetes: authoritative reviews have clearly outlined the impact of albuminuria in (non)-diabetic nephropathy. 105 
Baseline albuminuria as a predictor of albuminuria progression
We recently found that subjects with albuminuria levels 15-30 mg/24 hours had the highest risk for the incidence of microalbuminuria in the non-diabetic general population (abstract; Stuveling, J Am Soc Nephrol 2003;14:679-80A). The risk of high-normal albuminuria was 20-fold relative to normoalbuminuria. Other population based studies in non-diabetic subjects did not implement the predictive value of baseline albuminuria as a determinant of incident microalbuminuria. 95 In the HOPE study, comprising of subjects with pre-existent cardiovascular disease, a high incidence of macroalbuminuria (albuminuira >300 mg/24 hr) was found. Baseline microalbuminuria appeared to be the most important determinant of subsequent progression to this stage of nephropathy by far (estimated odds ratio 17.5). 119 
Diabetes
Aside from blood pressure, smoking and glycemic control, albuminuria at baseline is one of the most important predictors of progression of albuminuria in type 1 and 2 diabetes mellitus as shown in several studies. 120, 121 Conclusion. Albuminuria at a low level bears much information as a cardiovascular risk determinant in order to identify subjects at increased CV risk. Aside from the impact of common risk factors in the progression of early nephropathy, the presence of a relatively high level of albuminuria is an important determinant of renal disease progression and albuminuria itself. Preliminary evidence suggests such a role in relatively healthy subjects also. 120 120
Von Willebrandfactor
vWF and CV outcome
A recent nested case-control study, including a meta-analysis, showed that increased von Willebrand factor (vWF) serum levels predicted incident coronary heart disease in the general population, of which the risk was twofold. 122 vWF is also associated with an increased risk of CV mortality among diabetic and non-diabetic subjects, in whome high levels increase the risk threefold. 68 
vWF: meachnisms of CV outcome
Although vWF has prothrombotic properties, it is indicated as a marker of endothelial function.
vWF is released upon endothelial cell activation. Thus, in case of endothelial cell damage with degranulation of Weibel-Palade bodies, it is hypothesized that a concomitant rise of vWF will occur in blood. Its values in blood are however raised in many clinical conditions which are not necessarily due to endothelial cell damage. 123 VWF may therefore lack specificity as a marker.
What mechanisms may be the link between increased vWF and CV outcome? First, increased levels of vWF may be indicative of a procoagulant state, eventually leading to CV events. Second, increases in vWF are often accompanied by increases in acute-phase proteins. In vitro, mediators of inflammation like complement and cytokines (IL-6, TNF-α) are potent stimulators of vWF release by endothelial cells. 123 Not surprisingly therefore, its correlation with CRP is relatively high compared to other risk factors. 122 Interestingly, despite this overlap of vWF and CRP, one study suggests independent effects of both markers in the prediction of mortality in type 2 diabetes. 100 This suggests that endothelial dysfunction and inflammation represent two different pathophysiological mechanisms leading to the same disease.
vWF: mechanisms and predictive value in renal outcome -GFR
General population
Whether elevated vWF levels in the population predict the decline of renal function in the population is unknown. A small cross-sectional study found that vWF is inversely related to creatinine clearance, 124 this relation however being explained by elevated homocysteine levels.
Diabetes
In microalbuminuric type 2 diabetes, subjects with elevated vWF levels had typical signs of diabetic nephropathy and retinopathy, whereas these features were absent in subjects with normal vWF levels. 125 This observation was confirmed in the EURODIAB type 1 diabetes study, which showed that vWF was associated with albuminuria only in the presence of retinopathy. 126 This led to the suggestion that microalbuminuria is only indicative of diabetic kidney damage in presence of endothelial dysfunction. This concept of heterogeneity is however challenged by others, who showed that this interaction was absent with respect to CV mortality. 127 
vWF: mechanisms and predictive value in renal outcome -Albuminuria
General population
In non-diabetic subjects of the general population, Jager et al were unable to show an increased incidence of microalbuminuria across levels of vWF. 95 However, in a representative sample of healthy subjects, Clausen et al prospectively found that elevated baseline vWF levels predicted progression of albuminuria over 4 years. 128 
Diabetes
In type 2 diabetes, a cross-sectional study showed a progressive rise in serum concentration of vWF with increasing urinary albumin excretion, independent of risk factors and prevalent atherosclerosis. 129 More supportive data revealed that elevated vWF levels were shown to be related to the incidence and progression of (micro)albuminuria in type 2 diabetic subjects. 100 These data underscore the concept that endothelial dysfunction precedes the onset of microvascular disease and nephropathy. This has been suggested by Stehouwer et al who found that increased vWF levels preceded the onset of microalbuminuria in type 1 diabetic subjects. 130 The development of hypertension may be an important mediator of this process in type 1 diabetes.
Conclusion.
Although the evidence is limited, there may be a role for vWF, as a marker of endothelial integrity, in the prediction of the development of CV and early renal disease.
Other markers
Markers of cellular leukocyte adhension
Increased levels of circulating soluble intercellular adhesion molecules-1 and vascular cell adhesion molecules-1 (sICAM-1, sVCAM-1) are related to an adverse CV outcome in high-risk patient groups 131, 132 and in relatively healthy subjects. [133] [134] [135] [136] [137] To some extent, this also applies for different selectins, another group of adhesion molecules. 135, 136 Some studies however were unable to show such a relation. 138, 139 Endothelial cells already express cellular adhesion molecules at a relatively early phase of the atherosclerotic process. During atherogenesis, they enhance recruitment of inflammatory cells to sites of atheroma development. 75 In renal disease, a similar role has been observed. In various animal models of kidney disease, the upregulation of cellular adhesion molecules plays a pivotal role in the recruitment of macrophages to the kidney, thereby inducing or amplifying the inflammatory process. ICAM-1 deficient diabetic mice are resistant to the development of diabetic nephropathy. 140 At the epidemiological level, it is unknown whether elevated levels of sICAM-1 or sVCAM-1 predict the decline of GFR. A cross-sectional study in type 1 diabetic subjects showed that microand macroalbuminuric subjects had higher serum levels of sVCAM-1 and sICAM-1 as compared to normoalbuminuric subjects. 141 The Hoorn study showed that elevated sVCAM-1 levels preceded the onset of microalbuminuria in non-diabetic subjects recruited from the population. 95 Stehouwer et al showed that elevated levels of these markers are related to the incidence of (micro)albuminuria in type 2 diabetic subjects. 100 
Markers of coagulation and fibrinolysis
Elevated systemic levels of plasminogen activator inhibitor-1 (PAI-1), an inhibitor of fibrinolysis, predict an adverse CV outcome in high-risk patients. 142 Another fibrinolytic protein, namely tissue-type plasminogen activator (t-PA), also predict CV events. 100, 143, 144 Thus, dysfunction of the coagulation/fibrinolysis system appears of major importance in the development of CV disease. The most frequently described CV marker of impaired fibrinolysis is PAI-1, which is produced by the vascular endothelium, but other tissues are also involved. Especially fat cells are able to produce large amounts of PAI-1: adipose PAI-1 levels highly correlate with plasma PAI-1 levels. 145 It is therefore not surprising that PAI-1 is implicated as a core factor in insulin resistance. 146 Dysregulation of fibrinolysis in insulin resistance may be a key mediator leading to CV events. Similarly, PAI-1 has been implicated in several renal pathologies, which include amongst others protein-overload proteinuria, hypertensive and diabetic nephropathy, ageing and glomerulosclerosis. 147 However, it is unclear whether elevated levels of PAI-1 antigen are able to predict adverse renal outcome at the population level. In the earlier mentioned study of Shlipak et al, it was shown that a battery of procoagulant factors (factor VIIc, factor VIIIc, plasminantiplasmin complex and D-dimer), among which PAI-1 was not measured, were strongly related to levels of decreased kidney function. 89 Hovind et al however did not find an association between elevated PAI-1 levels and decline of GFR over time in type 1 diabetic patients. 148 An independent association between PAI-1 and microalbuminuria in young adults has been reported. 149 Elevated levels of t-PA are related to the incidence and progression of (micro)albuminuria in type 2 diabetic subjects. 100 
123
Conclusion. Many other markers of atherosclerotic vascular disease appear to be predictors of CV disease in healthy subjects. The evidence appears quite consistent with few negative reports (Table 1) . Their predictive value for the development of nephropathy in the population and in diabetes remains to be established.
4.Biochemical risk markers: do we need them all?
The evidence that various risk markers relate to renal disease, CV disease and mortality is compelling. Meanwhile, the search for better and stronger risk markers continues. The list of risk markers mentioned in Table 1 can easily be extended and will probably be extended in the near future. The currently already important question is which of these risk markers in this comprehensive list should we use to identify subjects at increased risk? Do we need them all? Do we need combinations of markers, each marking a different aspect of disease?
As mentioned earlier, the cornerstones of CV risk prediction remain in the classical risk profile.
Importantly, the discussion concerning which risk markers should be used as an additive tool in risk prediction is not closed, neither for CRP, nor for albuminuria or other markers. Let's take CRP as an example. The majority of population-based studies relating elevated CRP levels to outcome
show an additive contribution of this marker beyond the risk held by classical risk factors (see references in Table 1 ). In addition, CRP has been shown additive to prothrombin fragment 1+2, 41 interleukin-6, 44,57 atherogenic infections, 46 macrophage inhibitory cytokine-1, 55 coronary calcium scores, 59 and intima-media thickness, 150 in population-based studies, and microalbuminuria in type 2 diabetic subjects. 100 Some investigators even state that CRP shows superior predictive performance relative to other markers. 38 On the other hand, the Hoorn study 68 , the Caerphilly Prospective Heart Disease study, 65 the Glostrup study, 67 the Quebec Cardiovascular study, 52 the Atherosclerosis Risk in Community (ARIC) study, 58 the Rotterdam study, 71 and the Health ABC study 72 did not find a significant relation between CRP and CV outcome beyond the classical repertoire of risk factors. Others show that CRP is not superior to markers like von Willebrand factor, 68 fibrinogen, 65 interleukin-6, 70, 72 lipoprotein-associated phospholipase A 2 , 66 tissue-type plasminogen activator 151 or leptin. 54 Thus, CRP most probably adds to the absolute risk held by classical risk factors in the population, while its contribution relative to other risk markers is less clear.
Reasons for these inconsistencies are numereous and may relate to differences in study design, study population (men vs women, elderly, diabetes et cetera), population size, number of events, (laboratory) assessment of risk factors, and other factors. Bias is always a main concern, but it is difficult to extract its source. An important point to consider here is the fact that some of these risk factors show considerable variability. In the majority of studies, novel markers have only been measured once, which yields a considerable underestimation of estimated risks. Further, comparing a less reproducible parameter with a highly reproducible marker yields spurious results. The predictive performance will certainly improve if risk markers are measured more than once over time. 64 None of these risk markers by themselves provide optimal sensitivity and specificity to identify subjects at risk. Of course, the latter arguments also hold true for blood pressure and cholesterol. Therefore, to better appreciate the (independent) role of novel risk markers relative to each other and to classical risk factors, their assessment has to be improved.
Importantly, we have to distinguish between the use of these markers in primary prevention and risk stratification in hopital. More simplified, whether a person has hypercholesterolemia does not matter in the coronary care unit and determination of cardiac tropinines will provide more useful information in this situation. In primary prevention, the determination of cholesterol levels will be more informative. Thus, each risk marker may have its specific value in risk prediction in different patient groups depending on its content and nature.
As far as the kidney is concerned, this field of research is in it developing stages and a similar process will be pursued as in CV disease prediction in general. Similar problems are at hand in research concerning renal disease progression. In diabetic renal disease, microalbuminuria is the only novel risk marker which appears to be of additional value in renal risk prediction, in prevention of renal disease progression, and even in cost-effectiveness of treatment.
In the earlier mentioned PREVEND study, we showed that both CRP and albuminuria add to the risk of CV and non-CV mortality in the general population. The estimated risks of death were comparable. Interestingly, the predictive performance of both markers was much better than classical risk factors like blood pressure and serum cholesterol, whereas smoking appeared to be of equal importance (abstract; Stuveling, J Am Soc Nephrol 2003;14:679-80A).
In conclusion, there is no consensus to which extent a combination of risk factors and markers will best predict the risk of CV and renal disease progression. Moreover, current risk scores may have to be reevaluated in future.
Drug effects on novel risk markers
In earlier paragraphs, we described the relative contribution of various risk markers to CV and renal outcome. Aside from their proposed role in CV risk prediction, they may be extremely useful when some intervention modifies this parameter and subsequently shows benefit on CV risk due to that 125 125 modification. Taking classical risk factors as an example first hypertension and hyperlipidemia have been shown important independent risk factors. It has been shown that blood pressure and cholesterol lowering interventions can modify these risk factors, and that the magnitude of effect on blood pressure and cholesterol by these drugs correlates with the extent of risk reduction. In primary and secondary kidney diseases, proteinuria is the best example in this context. Proteinuria is an independent risk factor for renal function decline over time, specific drugs are able to lower proteinuria beyond alterations in for example blood pressure, and the magnitude of proteinuria lowering correlates with the risk reduction in renal outcome. 152 Lately, there has been growing interest in the possibility that some of the clinical benefits of certain blood pressure lowering agents and especially statins are due to so-called pleiotropic effects. It means that they have effects that are not directly related to their blood pressure and lipid lowering effects. For example, interventions
in the renin-angiotensin and cholesterol synthesis system are well known because of their antiinflammatory effects. 153, 154 When this criterion is met, CRP could serve an additive marker in global risk assessment.
PPAR-γ agonists, which have not yet been shown to reduce 'hard' CV and renal endpoints, are a promising therapeutic option. PPAR-γ agonists are known as insulin sensitising agents and these drugs are used primarily in the treatment of type 2 diabetes. These drugs not only improve insulin sensitivity and glycemic control, but also have potentially favourable effects on other components of the metabolic syndrome. Several randomised trials show a reduction in classical risk factors (blood pressure, lipids, insulin resistance) and novel risk markers (Table 3 ). These effects seem profound. Interestingly, in all randomised trials performed to date, the reduction of a specific marker during intervention with a PPAR-γ agonist correlated with the improvement in insulin sensitivity. This fact underscores the role of these markers in the metabolic syndrome.
The ADOPT trial will determine whether monotherapy with rosiglitazone is effective on glycemic control, improvement of other metabolic parameters (including CRP, PAI-1) and progression of diabetic nephropathy. 158 Non-pharmacological intervention is an alternative to drug intervention. For example, weight loss lowers CRP and albuminuria levels in obese subjects. 82, 159 Quitting smoking reduces albuminuria, 117 but for CRP this is unknown. Life-style changes also have profound effects on insulin sensitivity, the fibrinolysis system and others. It is certainly possible that the improvement of surrogate markers may in part explain the benefits of lifestyle alterations with respect to CV risk.
Conclusions
Markers of progressive CV disease are close to come of value in clinical practice as an additive tool to the classical risk factors. These markers have been proposed from the viewpoint of plausible pathophysiological concepts in vascular disease. Although these concepts have mainly been investigated in cardiovascular disease, there is cumulating data and evidence for an important role in renal disease progression as well. Indeed, in view of the overlap between cardiovascular and renal risk factors, it is tempting to speculate that these novel risk markers will be able to predict accelerated decline of renal function in the population. In fact, some of these factors such as high-sensitive CRP and albuminuria are close to become valuable renal risk markers both for detecting the risk for disease progression as well as for the protective response to therapy. 
